Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Brief Summary: Triple-negative breast cancer (TNBC) has a relatively bad prognosis whereas there is no standard regimen. Some data showed that platins could improve the efficacy of advance TNBC. In this trial, it is the hypothesis that TP (docetaxel plus carboplatin) has a better efficacy than EC-T (epirubicin plus cyclophosphamide followed by docetaxel).


Options:
A: Arm Label: Pembrolizumab + Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Doxorubicin, Drug: Epirubicin, Drug: Cyclophosphamide, Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Doxorubicin, Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Placebo, Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Chemotherapy | Intervention Type: BIOLOGICAL; Name: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim; Assigned to Arm(s): Pembrolizumab + Chemotherapy, Placebo + Chemotherapy
B: Arm Label: T-DM1; Type: EXPERIMENTAL; Interventions: Drug: T-DM1 | Arm Label: T-DM1 + endocrine therapy; Type: EXPERIMENTAL; Interventions: Drug: T-DM1 | Arm Label: Trastuzumab + endocrine therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab | Intervention Type: DRUG; Name: T-DM1; Assigned to Arm(s): T-DM1, T-DM1 + endocrine therapy | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab + endocrine therapy
C: Arm Label: 6 cycles of PC adjuvant chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel Cisplatin | Arm Label: 3 cycles of FEC followed by 3 cycles of Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T) | Intervention Type: DRUG; Name: Paclitaxel Cisplatin; Assigned to Arm(s): 6 cycles of PC adjuvant chemotherapy | Intervention Type: DRUG; Name: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T); Assigned to Arm(s): 3 cycles of FEC followed by 3 cycles of Docetaxel
D: Arm Label: EC-T; Type: ACTIVE_COMPARATOR; Interventions: Drug: EC-T | Arm Label: TP; Type: EXPERIMENTAL; Interventions: Drug: TP | Intervention Type: DRUG; Name: EC-T; Assigned to Arm(s): EC-T | Intervention Type: DRUG; Name: TP; Assigned to Arm(s): TP

Answer: D